CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ARSA (ImmuneEditome ID:410)

1. Gene summary of enriched editing regions for ARSA

check button Gene summary
Gene informationGene symbol

ARSA

Gene ID

410

GeneSynonymsASA|MLD
GeneCytomap

22q13.33

GeneTypeprotein-coding
GeneDescriptionarylsulfatase A|cerebroside-sulfatase|epididymis secretory sperm binding protein
GeneModificationdate20230329
UniprotIDA0A0C4DFZ2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr22:50623496-50624392:-ENST00000608497.1ENSG00000100299.16ARSAexonicAluSp,AluJr,L2,AluSxchr22:50623496-50624392:-.alignment


Top

2. Tumor-specific enriched editing regions for ARSA


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr22:50623496-50624392:-BRCAEER1.0738e-02image
ENSG00000100299.16,ARSABRCAEAG1.1099e-02image
chr22:50623496-50624392:-LUSCEER3.8740e-03image
ENSG00000100299.16,ARSALUSCEAG3.9822e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000100299.16,ARSABRCAPathEAG1.8784e-024.8817e-020.0714image
chr22:50623496-50624392:-BRCAPathEER1.7712e-024.9768e-020.0711image
ENSG00000100299.16,ARSAESCACliEAG5.7494e-034.7011e-02-0.3856image
chr22:50623496-50624392:-ESCACliEER6.9549e-033.9744e-02-0.3981image
ENSG00000100299.16,ARSAMESOPathEAG4.4408e-022.1883e-02-0.3086image
chr22:50623496-50624392:-MESOPathEER4.4408e-022.1883e-02-0.3086image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ARSA


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr22:50623496-50624392:-DLBCEERENSG00000103335,PIEZO1-0.63053.9243e-025.6898e-04-0.5395imageNDDX3X;EIF4A3;FBL;FMR1;RANGAP1;SRSF1;SRSF7;TARDBPNAGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr22:50623496-50624392:-DLBCEERENSG00000165704,HPRT10.59134.4303e-022.5272e-030.4819imageNDDX3X;EIF4A3;FBL;FMR1;RANGAP1;SRSF1;SRSF7;TARDBPHPRT1Macrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr22:50623496-50624392:-DLBCEERENSG00000198892,SHISA4-0.60744.8715e-025.7466e-04-0.5392imageNEIF4A3;FBL;RANGAP1NAGSVA_HALLMARK_MYOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for ARSA


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr22:50623496-50624392:-
UVMEERIRENSG00000181523.8chr1780209281:80211187:80212070:802122180.39213.1353e-021.0937e-030.4402imageNDDX3X;EIF4A3;FBL;FMR1;RANGAP1;SRSF1;SRSF7;TARDBPNAGSVA_HALLMARK_G2M_CHECKPOINT

More results



Top

5. Enriched editing regions and immune infiltration for ARSA


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr22:50623496-50624392:-CHOLEERMacrophages_M11.4740e-020.4818image
ENSG00000100299.16,ARSACHOLEAGMacrophages_M11.5431e-020.4789image
chr22:50623496-50624392:-COADEERNeutrophils3.5517e-060.4427image
ENSG00000100299.16,ARSACOADEAGNeutrophils3.5517e-060.4427image
chr22:50623496-50624392:-DLBCEERNK_cells_resting2.1781e-020.3761image
ENSG00000100299.16,ARSADLBCEAGNK_cells_resting2.1781e-020.3761image
chr22:50623496-50624392:-ESCAEERPlasma_cells2.0679e-02-0.2464image
ENSG00000100299.16,ARSAESCAEAGPlasma_cells2.0883e-02-0.2460image
chr22:50623496-50624392:-GBMEERT_cells_CD83.9552e-03-0.2325image
ENSG00000100299.16,ARSAGBMEAGT_cells_CD84.4239e-03-0.2297image
ENSG00000100299.16,ARSAHNSCEAGNeutrophils4.9789e-020.1153image
chr22:50623496-50624392:-KICHEEREosinophils2.7984e-020.3140image
ENSG00000100299.16,ARSAKICHEAGEosinophils2.7984e-020.3140image
chr22:50623496-50624392:-KIRCEERT_cells_CD4_naive4.6810e-02-0.1162image
ENSG00000100299.16,ARSALAMLEAGT_cells_gamma_delta4.0776e-040.6419image
chr22:50623496-50624392:-LGGEERT_cells_CD4_naive1.8189e-03-0.1468image
ENSG00000100299.16,ARSALGGEAGT_cells_CD4_naive2.0299e-03-0.1451image
chr22:50623496-50624392:-LIHCEERB_cells_memory1.9186e-02-0.1725image
ENSG00000100299.16,ARSALIHCEAGB_cells_memory1.9186e-02-0.1725image
chr22:50623496-50624392:-LUSCEERT_cells_regulatory_(Tregs)4.1825e-02-0.1140image
ENSG00000100299.16,ARSALUSCEAGT_cells_regulatory_(Tregs)3.7180e-02-0.1167image
chr22:50623496-50624392:-MESOEERPlasma_cells2.1225e-02-0.3189image
ENSG00000100299.16,ARSAMESOEAGPlasma_cells2.1225e-02-0.3189image
chr22:50623496-50624392:-OVEEREosinophils2.2754e-020.1635image
ENSG00000100299.16,ARSAOVEAGEosinophils2.1167e-020.1650image
chr22:50623496-50624392:-PAADEERNK_cells_resting1.1791e-020.2116image
ENSG00000100299.16,ARSAPAADEAGNK_cells_resting1.1791e-020.2116image
chr22:50623496-50624392:-PCPGEERT_cells_CD84.3490e-030.2347image
ENSG00000100299.16,ARSAPCPGEAGT_cells_CD82.8159e-030.2455image
chr22:50623496-50624392:-SARCEERT_cells_CD4_memory_resting3.4652e-020.1671image
ENSG00000100299.16,ARSASARCEAGT_cells_CD4_memory_resting3.4652e-020.1671image
chr22:50623496-50624392:-SKCMEERDendritic_cells_activated1.5536e-040.1944image
ENSG00000100299.16,ARSASKCMEAGDendritic_cells_activated1.4426e-040.1953image
chr22:50623496-50624392:-STADEERT_cells_follicular_helper4.7635e-02-0.1495image
chr22:50623496-50624392:-TGCTEERDendritic_cells_resting4.6313e-020.3130image
ENSG00000100299.16,ARSATGCTEAGDendritic_cells_resting4.6313e-020.3130image
chr22:50623496-50624392:-THCAEERT_cells_CD4_memory_resting4.7057e-020.0902image
ENSG00000100299.16,ARSATHCAEAGMacrophages_M14.7120e-020.0902image
chr22:50623496-50624392:-THYMEERDendritic_cells_activated1.3791e-030.2912image
ENSG00000100299.16,ARSATHYMEAGDendritic_cells_activated1.4089e-030.2906image
chr22:50623496-50624392:-UCSEERPlasma_cells1.7678e-020.4301image
ENSG00000100299.16,ARSAUCSEAGPlasma_cells1.7678e-020.4301image
chr22:50623496-50624392:-UVMEERDendritic_cells_resting7.0215e-030.3391image
ENSG00000100299.16,ARSAUVMEAGDendritic_cells_resting7.2545e-030.3378image


Top

6. Enriched editing regions and immune gene sets for ARSA


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000100299.16,ARSABLCAGSVA_HALLMARK_SPERMATOGENESISEAG1.7423e-020.1388image
chr22:50623496-50624392:-BLCAGSVA_HALLMARK_SPERMATOGENESISEER1.7463e-020.1388image
ENSG00000100299.16,ARSABRCAGSVA_HALLMARK_HEME_METABOLISMEAG3.6446e-050.1484image
chr22:50623496-50624392:-BRCAGSVA_HALLMARK_HEME_METABOLISMEER3.3085e-050.1492image
ENSG00000100299.16,ARSACHOLGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.7892e-020.4695image
chr22:50623496-50624392:-CHOLGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.8364e-020.4678image
chr22:50623496-50624392:-DLBCGSVA_HALLMARK_E2F_TARGETSEER4.6391e-030.4552image
ENSG00000100299.16,ARSADLBCGSVA_HALLMARK_E2F_TARGETSEAG4.6391e-030.4552image
chr22:50623496-50624392:-GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER9.9021e-030.2086image
ENSG00000100299.16,ARSAGBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.3594e-020.1998image
chr22:50623496-50624392:-HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.6225e-020.1411image
ENSG00000100299.16,ARSAHNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.6605e-020.1406image
chr22:50623496-50624392:-KICHGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER4.8244e-020.2837image
ENSG00000100299.16,ARSAKICHGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.8244e-020.2837image
chr22:50623496-50624392:-KIRPGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.4197e-02-0.1406image
ENSG00000100299.16,ARSAKIRPGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.4077e-02-0.1407image
chr22:50623496-50624392:-LGGGSVA_HALLMARK_PROTEIN_SECRETIONEER1.7470e-050.2012image
ENSG00000100299.16,ARSALGGGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.4513e-050.2028image
ENSG00000100299.16,ARSALIHCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG9.6160e-030.1904image
chr22:50623496-50624392:-LIHCGSVA_HALLMARK_KRAS_SIGNALING_UPEER9.6160e-030.1904image
ENSG00000100299.16,ARSALUADGSVA_HALLMARK_MYC_TARGETS_V1EAG1.0659e-020.1439image
chr22:50623496-50624392:-LUADGSVA_HALLMARK_MYC_TARGETS_V1EER1.0830e-020.1436image
chr22:50623496-50624392:-LUSCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.9494e-040.2071image
ENSG00000100299.16,ARSALUSCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.9583e-040.2071image
chr22:50623496-50624392:-MESOGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.3515e-030.4129image
ENSG00000100299.16,ARSAMESOGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.3515e-030.4129image
ENSG00000100299.16,ARSAOVGSVA_HALLMARK_HEME_METABOLISMEAG4.3719e-020.1446image
chr22:50623496-50624392:-PAADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.4864e-020.1889image
ENSG00000100299.16,ARSAPAADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.4864e-020.1889image
chr22:50623496-50624392:-PCPGGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.2046e-020.2073image
ENSG00000100299.16,ARSAPCPGGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.7627e-020.1962image
chr22:50623496-50624392:-PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.0938e-030.1541image
ENSG00000100299.16,ARSAPRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG9.6882e-040.1557image
chr22:50623496-50624392:-READGSVA_HALLMARK_HEME_METABOLISMEER6.1636e-040.5241image
ENSG00000100299.16,ARSAREADGSVA_HALLMARK_HEME_METABOLISMEAG6.1636e-040.5241image
chr22:50623496-50624392:-SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.6931e-02-0.1886image
ENSG00000100299.16,ARSASARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.6931e-02-0.1886image
chr22:50623496-50624392:-SKCMGSVA_HALLMARK_ANGIOGENESISEER2.0873e-020.1194image
ENSG00000100299.16,ARSASKCMGSVA_HALLMARK_ANGIOGENESISEAG1.8920e-020.1213image
chr22:50623496-50624392:-TGCTGSVA_HALLMARK_PEROXISOMEEER6.6390e-030.4173image
ENSG00000100299.16,ARSATGCTGSVA_HALLMARK_PEROXISOMEEAG6.6390e-030.4173image
chr22:50623496-50624392:-THCAGSVA_HALLMARK_UV_RESPONSE_DNEER8.7152e-040.1507image
ENSG00000100299.16,ARSATHCAGSVA_HALLMARK_UV_RESPONSE_DNEAG7.0851e-040.1532image
ENSG00000100299.16,ARSATHYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.9077e-020.2010image
chr22:50623496-50624392:-THYMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.9373e-020.2006image
ENSG00000100299.16,ARSAUCECGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.1656e-020.2376image
chr22:50623496-50624392:-UCECGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1595e-020.2378image
ENSG00000100299.16,ARSAUCSGSVA_HALLMARK_MYOGENESISEAG4.0917e-030.5088image
chr22:50623496-50624392:-UCSGSVA_HALLMARK_MYOGENESISEER4.0917e-030.5088image
ENSG00000100299.16,ARSAUVMGSVA_HALLMARK_HEME_METABOLISMEAG1.0368e-02-0.3233image
chr22:50623496-50624392:-UVMGSVA_HALLMARK_HEME_METABOLISMEER9.2106e-03-0.3282image


Top

7. Enriched editing regions and drugs for ARSA


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr22:50623496-50624392:-ACCBMS.754807EER2.6174e-03-0.4744image
ENSG00000100299.16,ARSAACCBMS.754807EAG2.6174e-03-0.4744image
ENSG00000100299.16,ARSABLCAABT.263EAG2.2042e-03-0.1782image
chr22:50623496-50624392:-BLCAABT.263EER2.4079e-03-0.1766image
ENSG00000100299.16,ARSABRCAGefitinibEAG2.6141e-020.0807image
chr22:50623496-50624392:-BRCAGefitinibEER2.5840e-020.0808image
chr22:50623496-50624392:-CESCCMKEER2.2604e-020.1537image
ENSG00000100299.16,ARSACESCCMKEAG2.1153e-020.1554image
chr22:50623496-50624392:-CHOLMethotrexateEER1.8910e-02-0.4753image
ENSG00000100299.16,ARSACHOLMethotrexateEAG2.5883e-02-0.4539image
chr22:50623496-50624392:-COADGW843682XEER7.6383e-030.2640image
ENSG00000100299.16,ARSACOADGW843682XEAG7.6383e-030.2640image
ENSG00000100299.16,ARSADLBCAZD6244EAG1.9456e-020.3825image
chr22:50623496-50624392:-DLBCAZD6244EER1.9456e-020.3825image
chr22:50623496-50624392:-ESCAImatinibEER4.0394e-02-0.2190image
ENSG00000100299.16,ARSAGBMAZD.2281EAG1.8047e-020.1916image
chr22:50623496-50624392:-GBMAZD.2281EER1.4957e-020.1971image
chr22:50623496-50624392:-HNSCMG.132EER1.6589e-020.1408image
ENSG00000100299.16,ARSAHNSCMG.132EAG1.5571e-020.1422image
chr22:50623496-50624392:-KICHDasatinibEER2.0384e-020.3339image
ENSG00000100299.16,ARSAKICHDasatinibEAG2.0384e-020.3339image
chr22:50623496-50624392:-KIRCBIRB.0796EER1.6850e-030.1827image
ENSG00000100299.16,ARSAKIRCBIRB.0796EAG5.8992e-030.1600image
chr22:50623496-50624392:-KIRPAZD.2281EER1.9414e-020.1457image
ENSG00000100299.16,ARSAKIRPAZD.2281EAG1.9969e-020.1451image
chr22:50623496-50624392:-LGGAZD6244EER1.9141e-050.2002image
ENSG00000100299.16,ARSALGGAZD6244EAG3.8596e-050.1927image
chr22:50623496-50624392:-LIHCGDC0941EER7.1728e-03-0.1981image
ENSG00000100299.16,ARSALIHCGDC0941EAG7.1728e-03-0.1981image
ENSG00000100299.16,ARSALUADFH535EAG2.4645e-020.1268image
chr22:50623496-50624392:-LUADFH535EER2.4814e-020.1267image
ENSG00000100299.16,ARSALUSCMG.132EAG1.8648e-03-0.1735image
chr22:50623496-50624392:-LUSCMG.132EER1.9708e-03-0.1726image
ENSG00000100299.16,ARSAMESOGDC.0449EAG1.0617e-030.4412image
chr22:50623496-50624392:-MESOGDC.0449EER1.0617e-030.4412image
chr22:50623496-50624392:-OVKU.55933EER1.7911e-03-0.2234image
ENSG00000100299.16,ARSAOVKU.55933EAG1.6100e-03-0.2250image
ENSG00000100299.16,ARSAPAADFH535EAG3.1517e-02-0.1819image
chr22:50623496-50624392:-PAADFH535EER3.1517e-02-0.1819image
ENSG00000100299.16,ARSAPCPGBX.795EAG9.0578e-030.2153image
chr22:50623496-50624392:-PCPGBX.795EER7.1782e-030.2216image
chr22:50623496-50624392:-PRADEtoposideEER3.7241e-060.2170image
ENSG00000100299.16,ARSAPRADEtoposideEAG2.9986e-060.2191image
chr22:50623496-50624392:-READAKT.inhibitor.VIIIEER8.0309e-04-0.5146image
ENSG00000100299.16,ARSAREADAKT.inhibitor.VIIIEAG8.0309e-04-0.5146image
chr22:50623496-50624392:-SARCGDC.0449EER3.5110e-030.2295image
ENSG00000100299.16,ARSASARCGDC.0449EAG3.5110e-030.2295image
ENSG00000100299.16,ARSASKCMLapatinibEAG1.0668e-04-0.1998image
chr22:50623496-50624392:-SKCMLapatinibEER1.0526e-04-0.2000image
chr22:50623496-50624392:-TGCTAG.014699EER9.0906e-030.4025image
ENSG00000100299.16,ARSATGCTAG.014699EAG9.0906e-030.4025image
chr22:50623496-50624392:-THCADMOGEER3.5012e-04-0.1617image
ENSG00000100299.16,ARSATHCADMOGEAG2.3726e-04-0.1662image
ENSG00000100299.16,ARSATHYMABT.888EAG4.3908e-03-0.2605image
chr22:50623496-50624392:-THYMABT.888EER4.6949e-03-0.2586image
ENSG00000100299.16,ARSAUCECABT.263EAG4.3936e-02-0.1908image
chr22:50623496-50624392:-UCECABT.263EER4.4429e-02-0.1903image
ENSG00000100299.16,ARSAUCSGW.441756EAG3.8463e-030.5117image
chr22:50623496-50624392:-UCSGW.441756EER3.8463e-030.5117image
ENSG00000100299.16,ARSAUVMCMKEAG4.4894e-02-0.2557image
chr22:50623496-50624392:-UVMCMKEER4.6035e-02-0.2544image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType